MarketBeat
14 Aug 2026, 05:04 UTC · 2h ago
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
14 Aug 2026, 05:04 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
UnitedHealth Group has decided to provide broad coverage for Guardant's Shield colorectal cancer screening test. — Coverage by the largest US health insurer significantly expands the addressable market and ensures reliable revenue streams for a key product.
+0.80Guardant expects an enhanced Shield workflow to reduce cost of goods sold (COGS) by 15% by year-end, targeting a $200 COGS against a $700+ selling price by 2028. — Significant margin expansion potential directly impacts the path to profitability for the screening business.
+0.60Guardant's MRD business (Reveal test) grew more than 100% year-over-year. — Strong growth in the high-value MRD segment demonstrates product-market fit and scaling capability.
+0.50Continue reading
6 related stories
Search tags
The company does not expect another major payer coverage decision for Shield before the end of 2026. — This creates a ceiling on immediate growth acceleration from the payer side for the next two years.
-0.30Guardant expects to achieve ADLT designation for Guardant360 Liquid CDx in the first half of 2027. — While positive for long-term reimbursement, the distant timeline means no immediate material impact on current financials.
+0.20Which stocks this story touches
Reported strong growth across all business segments, significant volume increases in Shield and Reveal, and expanding payer coverage.
Mentioned in a positive context regarding its decision to provide broad coverage for a cancer screening test.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
